Multiple Sclerosis Clinical Trials in New York

Showing 101-120 of 385 trials

Topotecan by Intracerebral Clysis for Recurrent Primary Malignant Brain Tumors

NCT00308165

This study will evaluate the safety and efficacy of a chemotherapeutic drug (topotecan) as it is given directly into brain tumors by a delivery technique called convection-enhanced delivery. This drug has been used for different types of cancer, but in this study it will be given by an experimental delivery technique designed to maximize the amount of drug delivered to the brain tumor and minimize the side effects in other parts of the body. This study will also evaluate advanced magnetic resonance (MR) imaging techniques. The study will assess quality of life parameters throughout the follow-up period.

Brain Neoplasms, Primary Malignant

Jeffrey N. Bruce16 participantsStarted Mar 2004

New York, New York, United States

ACTIVE_NOT_RECRUITINGPHASE1< 1 mile

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

NCT04603001

This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent isocitrate dehydrogenase (IDH) inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who may have received standard therapy

Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)Chronic Myelomonocytic Leukemia (CMML)+1 more

Eli Lilly and Company260 participantsStarted Nov 2020

Duarte, California, United States • Los Angeles, California, United States • Sacramento, California, United States +34 more locations

Topotecan by Intracerebral Clysis for Recurrent Primary Malignant Brain Tumors

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Multiple Sclerosis Trials in Other Cities

Mobile CBT for Middle Aged and Older Adults

A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

Study of the Safety of MRI Scans in People Who Have Breast Tissue Expanders After Mastectomy

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

A Study of PF-07260437 in Advanced or Metastatic Solid Tumors

Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol

Observational Study of Persistence on Bafiertam Treatment in Routine Clinical Practice

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)

A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases

Portable Neuromodulation Stimulator Registry for People With Multiple Sclerosis

A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors

Bevonescein to Highlight Nerves in Patients Undergoing Head & Neck Surgery

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

ProVIDE II Bridging Study

Other Conditions in New York